Accuracy, Completeness, and Transparency: lessons from Tamiflu experience
|
|
- Sandra Harvey
- 5 years ago
- Views:
Transcription
1 Accuracy, Completeness, and Transparency: lessons from Tamiflu experience Peter Doshi, PhD Postdoctoral fellow in Comparative Effectiveness Research Johns Hopkins University School of Medicine October 12, 2012 ACT Now EQUATOR Conference, Freiburg, Germany T. Jefferson :: R. Hama :: C. Heneghan :: C. Del Mar :: P. Doshi :: M Jones :: M Thompson
2 CHAPTER 1: Conclusions of great benefit
3 The Tamiflu Success Story
4 CDC/ACIP Influenza Rec. (2006) Among influenza virus infected participants in 10 clinical trials, the risk for pneumonia among those participants receiving oseltamivir was approximately 50% lower than among those persons receiving a placebo (339). A similar significant reduction was also found for hospital admissions; a 50% reduction was observed in the small subset of highrisk participants, although this reduction was not statistically significant. Kaiser 2003 Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA. Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep Jul 28;55(RR-10):
5 HHS Pandemic Influenza Plan (2005) Critical assumptions. Treatment with a neuraminidase inhibitor (oseltamivir [Tamiflu ] or zanamivir [Relenza ]) will be effective in decreasing risk of pneumonia, will decrease hospitalization by about half (as shown for interpandemic influenza), and will also decrease mortality. (p.d-20) U.S. Department of Health and Human Services. HHS Pandemic Influenza Plan [Internet] [cited 2009 Jun 9]. 5
6 HHS 2004 draft pandemic plan The impacts of oseltamivir therapy on lower respiratory tract complications (LRTCs) of influenza and on influenza hospitalizations were calculated in a pooled analysis of 10 randomized placebo-controlled studies that included 3,591 adults and adolescents. Overall, 4.6 percent of oseltamivir treated persons had an LRTC of influenza infection compared with 10.3 percent of persons who received placebo a 55 percent reduction (P<0.001). Kaiser 2003 HHS. DRAFT Pandemic Influenza Preparedness and Response Plan [cited 2010 Jul 5]. 6 emiccore.pdf
7 CHAPTER 1: Conclusions of great benefit CHAPTER 2: Conclusions challenged
8 The Tamiflu Story April July
9 Hayashi s criticism Kaiser 2003 is a Roche authored paper Pooled analysis of 10 Roche funded RCTs from the late 1990s 2/10 published (1397 pts) 8/10 never published (2691 pts) Kaiser et al. Archives of Internal Medicine. 2003; 163: Conclusion: Oseltamivir treatment of influenza illness reduces LRTCs, antibiotic use, and hospitalization in both healthy and at-risk adults. 9
10 CHAPTER 1: Conclusions of great benefit CHAPTER 2: Conclusions challenged CHAPTER 3: Evidence is missing
11 Profs Kaiser and Hayden I suggest to contact Roche directly to get access to the files. from Kaiser August 17, 2009 Slide courtesy Tom Jefferson I have searched but cannot find the original files related to this 2003 publication. Before and again after my 2+ years at WHO in Geneva, I was obliged to move offices at the University several times and downsize. The files appear to have been discarded. My co-author Laurent Kaiser, now professor at the University of Geneva, is copied on this reply, as he may have his own sources. The questions posed by the inquirer are not clear to me, but if original data or unpublished study reports are required, they will likely need to come from Roche, the sponsor of these studies. from Hayden August 14, 2009
12 Professor John Treanor Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA Feb 23;283(8):
13 Professor Karl Nicholson Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet May 27;355(9218):
14 I did not perform an independent analysis of the primary data, which was not required or requested by JAMA at the time of submission, and I do not have access to the primary data, which I also never requested. When asked a similar question, Nicholson said he did not recall seeing the primary data. He said that the statistical analysis had been conducted by Roche and he analysed the summary data. Quotes from Cohen D. Complications: tracking down the data on oseltamivir. BMJ Dec 8;339(dec08_3):b5387.
15 Largest treatment trial abstract only Source: Cohen D. Complications: tracking down the data on oseltamivir. BMJ. 2009;339:b5387.
16 Issues to consider What is the role of trust in the scientific publication and evidence synthesis process? Do named authors have a responsibility to provide data that allows for independent verification of claims? What is one to conclude in the absence of obtaining data for trials that are known to exist?
17 Dec. 2009
18 Cochrane review, Dec 2009 Roche: very happy to have its data reviewed by appropriate authorities or individuals full study reports will also be made available on a password-protected site within the coming days to physicians and scientists undertaking legitimate analyses. Full study report?
19
20 Doshi P, Jones M, Jefferson T. Rethinking credible evidence synthesis. BMJ. 2012;344:d7898.
21
22 New Methods Discussed new methods Identify all trials (trial programme) No more published papers! Identify and retrieve all Clinical Study Reports and regulatory material Table of Contents of the Evidence (TOCE) Weave evidence of trial programmes together Assess if reliable, analyse Group decision Agree Agree Agree Agree Disagree What does reliable mean? Complete? Trustworthy? (Both?) (Original slide courtesy Tom Jefferson)
23 CHAPTER 1: Conclusions of great benefit CHAPTER 2: Conclusions challenged CHAPTER 3: Evidence is missing CHAPTER 4: Some (20,000 pages) evidence retrieved
24 EMA s sea-change in attitude November 30, 2010
25 What we obtained from EMA Trial(s) No of patients Pages obtained JV JV M ML ML MV NP NV NV WP WV WV Trial(s) No of patients Pages obtained WV15673/ WV WV WV WV WV15759/ WV WV15812/ WV WV15876/15819/ WV WV Total
26 Paper needed to print Clinical Study Report for oseltamivir trial WP pages
27 Unexpected findings
28 CERTIFICATE OF ANALYSIS
29 CHAPTER 1: Conclusions of great benefit CHAPTER 2: Conclusions challenged CHAPTER 3: Evidence is missing CHAPTER 4: Some (20,000 pages) evidence retrieved CHAPTER 5: Conclusions of little benefit
30 Latest Cochrane Review (2012) January 2012 Conclusions: ~1 day reduction in time to first alleviation of influenza symptoms No decrease in risk of hospitalization No evidence it can stop the spread of virus Suggestive evidence Tamiflu interferes with natural influenza antibody production
31 Roche: Tamiflu reduces incidence of secondary complications (ie bacterial infections) by 45% FDA: Claim not supported by substantial evidence. Roche promotional material FDA Warning Letter 31
32 Tamiflu label Serious bacterial infections may begin with influenza-like symptoms or may coexist with or occur as complications during the course of influenza. TAMIFLU has not been shown to prevent such complications. Tamiflu Product Labeling (Nov 17, 2000 to present) Before 2009, CHF 7.6 billion worth stockpiled by governments worldwide. Why? 32
33 CHAPTER 1: Conclusions of great benefit CHAPTER 2: Conclusions challenged CHAPTER 3: Evidence is missing CHAPTER 4: Some (20,000 pages) evidence retrieved CHAPTER 5: Conclusions of little benefit
Hayashi s Problem. Tom Jefferson Cochrane ARI group
Hayashi s Problem Tom Jefferson Cochrane ARI group jefferson.tom@gmail.com Hello I am Tom Jefferson. This is what my friends say of my work: it is mind boggling that medical journals that publish Dr. Jefferson's
More informationHayhasi s problem. Tom Jefferson Cochrane ARI group (thanks to Peter Doshi, Deborah Cohen, NIHR and all my co-reviewers)
Hayhasi s problem The use of regulatory information for research synthesis Tom Jefferson Cochrane ARI group jefferson.tom@gmail.com (thanks to Peter Doshi, Deborah Cohen, NIHR and all my co-reviewers)
More informationApplication for inclusion, change or deletion of a medicine in the WHO Model List of Essential Medicines
Application for inclusion, change or deletion of a medicine in the WHO Model List of Essential Medicines We are a group of authors within an external affiliated non-government organisation, the Cochrane
More informationHOW EFFECTIVE ARE ANTIVIRAL DRUGS AGAINST INFLUENZA? Dr Puja Myles
HOW EFFECTIVE ARE ANTIVIRAL DRUGS AGAINST INFLUENZA? Dr Puja Myles Puja.myles@nottingham.ac.uk ANTIVIRALS CURRENTLY USED IN INFLUENZA Previously, M2-inhibitors (amantadine and rimantadine) From 1999, Neuraminidase
More informationInfluenza Therapies. Considerations Prescription influenza therapies require prior authorization through pharmacy services.
Influenza Therapies Policy Number: 5.01.515 Last Review: 10/2017 Origination: 10/2002 Next Review: 10/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for influenza
More informationTamiflu: A nice little earner
Tamiflu: A nice little earner (BMJ 2014 ) Dr Vanessa Jordan PhD New Zealand Cochrane Fellow Outline Tamiflu what is it? World response to the 2009 Flu pandemic Original systematic review findings The battle
More informationTelephone Triage of Patients with Influenza
Telephone Triage of Patients with Influenza JONATHAN L. TEMTE, MD, PhD University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin Published ahead of print (American Family Physician)
More informationApplication for inclusion, change or deletion of a medicine in the WHO Model List of Essential Medicines
Application for inclusion, change or deletion of a medicine in the WHO Model List of Essential Medicines We are a group of authors within an external affiliated non-government organisation, the Cochrane
More informationSkin reactions in patients with influenza treated with oseltamivir: a retrospective cohort study
Antiviral Therapy 9:187-195 Skin reactions in patients with influenza treated with oseltamivir: a retrospective cohort study Beth L Nordstrom 1 *, Kelly Oh 1, Susan T Sacks 2 and Gilbert J L Italien 1
More informationORIGINAL INVESTIGATION. Impact of Oseltamivir Treatment on Influenza-Related Lower Respiratory Tract Complications and Hospitalizations
Grippe 8701 ORIGINAL INVESTIGATION Impact of Treatment on Influenza-Related Lower Respiratory Tract Complications and Hospitalizations Laurent Kaiser, MD; Cynthia Wat, MBBS, MRCP; Tracy Mills, MSc; Paul
More informationOseltamivir: Do the recommendations reflect the evidence? ERIC KRUEGER, MD
Oseltamivir: Do the recommendations reflect the evidence? ERIC KRUEGER, MD ADVOCATE LUTHERAN GENERAL HOSPITAL UNIVERSITY OF ILLINOIS - CHICAGO ACOEP SPRING SYMPOSIUM APRIL 3, 2018 Financial Disclosures
More informationAccess to clinical trial information and the stockpiling of Tamiflu. Department of Health
MEMORANDUM FOR THE COMMITTEE OF PUBLIC ACCOUNTS HC 125 SESSION 2013-14 21 MAY 2013 Department of Health Access to clinical trial information and the stockpiling of Tamiflu 4 Summary Access to clinical
More informationAttacking The Flu Bug The Pharmacist s s Pro-Active Role in Preventing & Treating Influenza
Attacking The Flu Bug The Pharmacist s s Pro-Active Role in Preventing & Treating Influenza Catherine E. Cooke, PharmD, BCPS, PAHM This program has been brought to you by PharmCon Attacking The Flu Bug
More informationRESEARCH. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and metaanalysis
Neuraminidase for preventing and treating influenza in healthy adults: systematic review and metaanalysis Tom Jefferson, researcher, 1 Mark Jones, statistician, 2 Peter Doshi, doctoral student, 3 Chris
More informationSupplementary material: use of neuraminidase inhibitors in influenza
Supplementary material: use of neuraminidase inhibitors in influenza Introduction This document supplements the Academy of Medical Sciences and Wellcome Trust s steering group report on the treatment of
More informationEffectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and
Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials Nicola J Cooper, Alexander J Sutton, Keith
More informationDebate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza
Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza Aeron Hurt WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia www.influenzacentre.org NA inhibitor
More informationThe influenza season
Management of influenza infection in children and pregnant women in BC, an update Immunization is the main preventive measure against influenza viruses. However, for certain patients who develop infection
More information10 3 pfu A B 2004/ FluA. Viral Shedding. Viral Shedding. Frank Houston Family Study 2005/
56 pp.109-1162006 6. 1 2 1 2 10 3 pfu A B 2004/2005 1500 1700 120 1000 1500 420 50 Viral Shedding Frank 1975 1980 Houston Family Study 12 4 A 110-8645 2 23 16 TEL 03-3833-8381 FAX 03-3831-9488 E-mail mitamura@eijuhp.com
More informationFPIN's Clinical Inquiries. What Is the Best Antiviral Agent for Influenza Infection? Searchable Question
FPIN's Clinical Inquiries What Is the Best Antiviral Agent for Influenza Infection? Searchable Question What is the best antiviral treatment for influenza? Evidence-Based Answer Four antiviral agents have
More informationThank you for sending us the assessment report for the above technology appraisal. Our response is provided below.
xxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx Tuesday 29 th July 2008 Amy Burke National Institute for Health and Clinical Excellence MidCity Place 71 High Holborn London WC1V 6NA BY E-MAIL Dear
More informationIn 1997, avian influenzavirus was shown to infect
Pandemic Influenza and Healthcare Demand in the Netherlands: Scenario Analysis Marianne L.L. van Genugten,* Marie-Louise A. Heijnen,* and Johannes C. Jager* In accordance with World Health Organization
More informationAntivirals for Avian Influenza Outbreaks
Antivirals for Avian Influenza Outbreaks Issues in Influenza Pandemic Preparedness 1. Surveillance for pandemic preparedness eg. H5N1 2. Public health intervention eg. efficacy, feasibility and impact
More informationPatient Knowledge and Attitudes about Antiviral Medication and Vaccination for Influenza in an Internal Medicine Clinic
MAJOR ARTICLE Patient Knowledge and Attitudes about Antiviral Medication and Vaccination for Influenza in an Internal Medicine Clinic Michael A. Gaglia, Jr., 1,2 Robert L. Cook, 3 Kevin L. Kraemer, 1 Michael
More informationOseltamivir for Treatment of Influenza in Healthy Adults: Pooled Trial Evidence and Cost-Effectiveness Model for Canada
Volume 6 Number 2 2003 VALUE IN HEALTH Oseltamivir for Treatment of Influenza in Healthy Adults: Pooled Trial Evidence and Cost-Effectiveness Model for Canada Bernie J. O Brien, PhD, 1,2 Ron Goeree, MA,
More informationsamedi 17 octobre 2009 MJA 2009, 191:142
1 MJA 2009, 191:142 2 MJA 2009, 191:142 3 4 CDC Interim Recommendations for Oseltamivir and Zanamivir Patient Categories for Treatment 1.Recommended: all patients hospitalized with suspected or confirmed
More informationPandemic Influenza Preparedness and Response
Pandemic Influenza Preparedness and Response US Department of Health and Human Services Bruce Gellin, MD, MPH Director, National Vaccine Program Office The pandemic influenza clock is ticking. We just
More informationSafety of neuraminidase inhibitors for influenza
Bond University epublications@bond Faculty of Health Sciences & Medicine Publications Faculty of Health Sciences & Medicine 9-1-2006 Mark Jones University of Queensland Chris Del Mar Bond University, chris_del_mar@bond.edu.au
More informationTHIS ACTIVITY HAS EXPIRED. CME CREDIT IS NO LONGER AVAILABLE
THIS ACTIVITY HAS EXPIRED. CME CREDIT IS NO LONGER AVAILABLE The following content is provided for informational purposes only. PREVENTION AND CONTROL OF INFLUENZA Lisa McHugh, MPH Influenza can be a serious
More informationRISK GROUPS FOR THE A(H1N1) PANDEMIC 2009
5 PANDEMIA DE GRIPĂ A(H1N1), 2009 RISK GROUPS FOR THE A(H1N1) PANDEMIC 2009 European Center for Disease Prevention and Control Pandemic H1N1 2009 Risk Assessment 176 177 178 179 SELECTIVE BIBLIOGRAPHY
More informationInfluenza A 6/23/2010. Lisa Winston, MD UCSF / San Francisco General Hospital Divisions of Infectious Diseases and Hospital Medicine
Influenza Update in a Pandemic Year Nothing to disclose. Lisa Winston, MD UCSF / San Francisco General Hospital Divisions of Infectious Diseases and Hospital Medicine Influenza Biology Influenza Biology
More informationPandemic Influenza Preparedness
Pandemic Influenza Preparedness Of the many health threats that we are preparing for, this is the one that we know will happen. Bruce G. Gellin, MD, MPH Director, National Vaccine Program Office Department
More informationOseltamivir (Tamiflu ) for Acute Influenza. John Collins Spring 2014 BME 270
Oseltamivir (Tamiflu ) for Acute Influenza John Collins Spring 2014 BME 270 Key Points About Oseltamivir for Treating Acute Influenza Infections Influenza = RNA virus (replicates genome by RNA- dependent
More informationInfluenza is a common respiratory illness responsible
INVITED COMMENTARY Prevention and Control of Influenza: No Easy Task Kristina Simeonsson, Zack Moore Every influenza season presents different challenges: Novel viruses emerge, new groups of people are
More informationTamiflu. Tamiflu (oseltamivir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.19 Subject: Tamiflu Page: 1 of 5 Last Review Date: March 18, 2016 Tamiflu Description Tamiflu (oseltamivir)
More informationMethodological Considerations for Controlled Influenza Treatment Studies in CAM
Methodological Considerations for Controlled *This paper is currently submitted to and under review at the Journal of Alternative and Complementary Medicine, document #JACM-2009-0212. The pre-publication
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Xofluza) Reference Number: CP.PMN.185 Effective Date: 10.30.18 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationClinical Policy Title: Seasonal influenza testing
Clinical Policy Title: Seasonal influenza testing Clinical Policy Number: 07.01.08 Effective Date: October 1, 2017 Initial Review Date: August 17, 2017 Most Recent Review Date: September 21, 2017 Next
More information1/31/2013 DISEASE BASICS. Influenza; Implications for Public Health Professionals. Influenza: An Age-Old Disease, A Disease for All Ages
Influenza; Implications for Public Health Professionals Phillip L. Barkley, M.D. Director of Student Health University of Florida DISEASE BASICS Influenza: An Age-Old Disease, A Disease for All Ages Epidemics
More informationPandemic Influenza Planning at Kaiser Permanente
Pandemic Influenza Planning at Kaiser Permanente Skip Skivington, MBA Interim Vice President of Supply Chain Kaiser Foundation Health Plan, Inc. Eric Koscove, MD Emergency Medicine Santa Clara Medical
More informationWhat s New in Flu? An Update on Influenza Prevention and Treatment
What s New in Flu? An Update on Influenza Prevention and Treatment Kathryn M. Edwards MD Sarah H. Sell and Cornelius Vanderbilt Professor of Pediatrics Vanderbilt University Nashville, TN, USA Disclosures
More informationOutbreak Response/Epidemiology Influenza Weekly Report Arkansas
Nathaniel Smith, MD, MPH, Director and State Health Officer Outbreak Response/Epidemiology Influenza Weekly Report Arkansas 2018-2019 Week Ending Saturday 10/20/2018 Dirk Haselow, MD, PhD State Epidemiologist,
More informationPANDEMIC INFLUENZA IN THE WORKPLACE
PANDEMIC INFLUENZA IN THE WORKPLACE 1 WILLIAM CANDLER, D.O., M.T.M.& H. Medical Director John Deere Harvester Works, Seeding Group and Cylinder Division Proposed Crisis Management Structure CORPORATE CRISIS
More informationRISK FACTORS FOR HOSPITALIZATION AMONG CHILDREN WITH INFLUENZA B INFECTION
Southeast Asian J Trop Med Public Health RISK FACTORS FOR HOSPITALIZATION AMONG CHILDREN WITH INFLUENZA B INFECTION Visal Moolasart and Weerawat Manosuthi Bamrasnaradura Infectious Diseases Institute,
More informationBattle against Respiratory Viruses (BRaVe)
Battle against Respiratory Viruses (BRaVe) Dr Sylvie BRIAND Director Pandemic and Epidemic Diseases World Health Organization, Geneva Burden of acute respiratory infections Acute respiratory infections
More informationProphylaxis and Treatment for Influenza among the Elderly
Respiratory Diseases in the Elderly Prophylaxis and Treatment for Influenza among the Elderly JMAJ 45(6): 245 250, 2002 Hajime GOTO Professor, The First Department of Internal Medicine, Kyorin University
More informationPANDEMIC INTERVENTIONS WEIGHING THE OPTIONS TO PROTECT YOUR WORKFORCE
PANDEMIC INTERVENTIONS WEIGHING THE OPTIONS TO PROTECT YOUR WORKFORCE Presented by Dr. Allan Holmes President, Global Medical Services / Global Consulting PRESENTATION OBJECTIVES Pandemic still a threat
More informationSection 6: Delivery of Antiviral Drugs
Section 6: Delivery of Antiviral Drugs OVERVIEW Antiviral drugs are an important adjunct to influenza vaccine for the prevention and control of seasonal influenza. Use of antiviral drugs for prophylaxis
More informationUpdate on pandemic influenza A(H1N1) activity, United States
Update on pandemic influenza A(H1N1) activity, United States Joseph Bresee, MD Chief, Epidemiology and Prevention Branch Influenza Division, NCIRD Centers for Diseases Control and Prevention September
More informationNEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE Thomas R. Frieden, MD, MPH Commissioner
NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE Thomas R. Frieden, MD, MPH Commissioner Interim Guidance on Dosage, Precautions, and Adverse Effects of Antiviral Medications used to Treat or Prevent
More informationInfluenza : What is going on? How can Community Health Centers help their patients?
Influenza 2008-2009: What is going on? How can Community Health Centers help their patients? Beth Nivin Bureau of Communicable Diseases New York City Dept. of Health and Mental Hygiene By the end of this
More informationInfluenza Vaccine Are We In The Same Page? Jehad Abdalla.M.D Infectious Diseases Consultant Al Rahba Hospital Abu Dhabi - UAE
Influenza Vaccine Are We In The Same Page? Jehad Abdalla.M.D Infectious Diseases Consultant Al Rahba Hospital Abu Dhabi - UAE Objectives. Recognize Influenza types and characteristics. Recognize Influenza
More informationEstimates of Influenza Vaccination Coverage among Adults United States, Flu Season
Estimates of Influenza Vaccination Coverage among Adults United States, 2017 18 Flu Season On This Page Summary Methods Results Discussion Figure 1 Figure 2 Figure 3 Figure 4 Table 1 Additional Estimates
More information1. What is this study about? 2. Who is part of the PRIDE research consortium? 3. Who is funding this research?
FAQs relating to the Lancet Respiratory Medicine publication: Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection:
More informationPandemic Influenza influenza epidemic: realization of a worst-case scenario
Pandemic Influenza October 9, 2006 1918 influenza epidemic: realization of a worst-case scenario First case: Albert Mitchell, Camp Funston, KS, March 11, 1918 Up to 20% of all humans infected 20-50 million
More informationPandemic Influenza. Bradford H. Lee, MD Nevada State Health Officer. Public Health: Working for a Safer and Healthier Nevada
Pandemic Influenza Bradford H. Lee, MD Nevada State Health Officer EXHIBIT C Legislative Committee on Health Care Document consists of 29 slides. Entire document provided. Due to size limitations, pages
More informationGuideline for Antiviral Drugs
Guideline for Antiviral Drugs March 26, 2007 Pandemic Influenza Experts Advisory Committee 179 180 Guideline for Antiviral Drugs Distribution adjustment Before outbreak occurs in Japan Instruct medical
More informationEffect of rapid influenza testing on the clinical management of paediatric influenza
DOI:10.1111/j.1750-2659.2009.00079.x www.blackwellpublishing.com/influenza Original Article Effect of rapid influenza testing on the clinical management of paediatric influenza Lance C. Jennings, a,b Heino
More informationUS FDA approves XOFLUZA (Baloxavir Marboxil) new drug to treat influenza on 24 th Oct 2018
US FDA approves XOFLUZA (Baloxavir Marboxil) new drug to treat influenza on 24 th Oct 2018 Influenza Disease Burden What is Influenza? Facts and Figures (1) A common viral infection that can be deadly,
More informationH1N1 influenza pandemic ( Spanish flu ) probably killed million people globally. Seasonal flu can cause ,000 deaths (WHO).
Influenza-1918-2018. Are we ready for another pandemic? 1918-20 H1N1 influenza pandemic ( Spanish flu ) probably killed 50-100 million people globally. Seasonal flu can cause 250-500,000 deaths (WHO).
More informationCongregate Care Facilities
Congregate Care Facilities Information for Pierce County Long-Term Care Facilities vember 2017 Influenza Outbreak Guidelines Reporting Requirements Communicable Disease Division 3629 South D Street, Tacoma,
More informationCloudbreak. March Cidara Therapeutics
Cloudbreak March 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationINFLUENZA. Rob Young (James. J. Reid) Faculty of Medicine University of Auckland (Otago)
INFLUENZA Rob Young (James. J. Reid) Faculty of Medicine University of Auckland (Otago) INFLUENZA Don t confuse with the common cold Symptoms may be similar BUT those with influenza are sick those with
More informationLarge trials vs observational studies in assessing benefit and harm: the example of aprotinin
Large trials vs observational studies in assessing benefit and harm: the example of aprotinin Dean A. Fergusson, MHA, PhD Senior Scientist and Associate Director, Clinical Epidemiology Program, Ottawa
More informationHow Effective is the Flu Vaccine?
How Effective is the Flu Vaccine? Thousands of elderly Americans are lining up for hours to receive a flu shot. And the media are filled with stories about the inadequacy of the flu vaccine supply now
More informationThe Pandemic Ventilator
The Pandemic Ventilator Jeff Graansma Background When a new disease or virus spreads in a population that has never been exposed to that type before it is called a pandemic. It can affect whole continents
More informationFlu Watch. MMWR Week 3: January 14 to January 20, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance
Flu Watch MMWR Week 3: January 14 to January 2, 218 All data are provisional and subject to change as more reports are received. Geographic Spread South Carolina reported widespread activity this week.
More informationIS THE UK WELL PREPARED FOR A REPEAT OF THE 1918 INFLUENZA PANDEMIC?
Cambridge Judge Business School Centre for Risk Studies IS THE UK WELL PREPARED FOR A REPEAT OF THE 1918 INFLUENZA PANDEMIC? Dr Andrew Coburn Chief Scientist Cambridge Centre for Risk Studies 5 December
More informationEDINBURGH HEALTHCARE NHS TRUST. 4 Edinburgh Healthcare NHS Trust Printed Material,
Introduction 1 Board Minutes and Papers, 1994-1999 2 Related Board Papers, 1995-2001 3 Administrative Material, 1997-2001, n.d. 4 Edinburgh Healthcare NHS Trust Printed Material, 1995-1997 5 General Strategy
More informationOutbreak Response/Epidemiology Influenza Weekly Report Arkansas
Nathaniel Smith, MD, MPH, Director and State Health Officer Outbreak Response/Epidemiology Influenza Weekly Report Arkansas 7- Week Ending Saturday // Dirk Haselow, MD, PhD State Epidemiologist, Medical
More informationEfficacy And Tolerability Of The Neuraminidase Inhibitor Zanamivir
ISPUB.COM The Internet Journal of Infectious Diseases Volume 1 Number 1 Efficacy And Tolerability Of The Neuraminidase Inhibitor Zanamivir M Iozzo Citation M Iozzo.. The Internet Journal of Infectious
More informationFlu Watch. MMWR Week 4: January 21 to January 27, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance
Flu Watch MMWR Week 4: January 21 to January 27, 218 All data are provisional and subject to change as more reports are received. Geographic Spread South Carolina reported widespread activity this week.
More informationPlanning Recommendations for the Use of Anti-Influenza (Antiviral) Drugs in Canada During a Pandemic
Annex E Planning Recommendations for the Use of Anti-Influenza (Antiviral) Drugs in Canada During a Pandemic Date of Latest Version: October 2006 Summary of Significant Changes: Reflects the establishment
More informationSeptember Paul Lewis, MD. Deputy Tri-county Health Officer Clackamas, Multnomah, Washington Counties
H1N1 Clinician Update September 2009 Paul Lewis, MD Deputy Tri-county Health Officer Clackamas, Multnomah, Washington Counties Desired Outcomes 1. Understand the clinical implications of the H1N1 Influenza
More informationInfluenza. Tim Uyeki MD, MPH, MPP, FAAP
Influenza Tim Uyeki MD, MPH, MPP, FAAP Influenza Division National Center for Immunization and Respiratory Diseases Coordinating Center for Infectious Diseases Centers for Disease Control and Prevention
More informationOseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza Issued: September 2008 guidance.nice.org.uk/ta158 NICE has accredited the process used by the Centre for Health Technology
More informationPandemic influenza Recommendations on the use of antiviral medicines for pregnant women, women who are breastfeeding and children under the age of
Pandemic influenza Recommendations on the use of antiviral medicines for pregnant women, women who are breastfeeding and children under the age of one year Updated September 29 DH INFORMATION READER BOX
More informationGuidelines for clinical management of severe influenza infection. Aeron Hurt
Guidelines for clinical management of severe influenza infection Aeron Hurt Current WHO guidelines WHO guidance documents for the clinical management of influenza virus infection were published in 2007
More informationcolds and flu Introduction KEY MESSAGES
colds and flu New insights: Cold and flu Introduction Colds and flu are responsible for more visits to the pharmacy than any other infectious illness. While severity of influenza differs from year to year,
More informationCan Antiviral Drugs Contain Pandemic Influenza Transmission?
Can Antiviral Drugs Contain Pandemic Influenza Transmission? Niels G. Becker*, Dingcheng Wang National Centre for Epidemiology and Population Health, The Australian National University, Canberra, Australian
More information10 things you may not know about the Cochrane Library
10 things you may not know about the Cochrane Library Carol Lefebvre Independent Information Consultant Lefebvre Associates Ltd, Oxford, UK and Co-Convenor, Cochrane Information Retrieval Methods Group
More informationAlberta Health. Seasonal Influenza in Alberta Season. Analytics and Performance Reporting Branch
Alberta Health Seasonal Influenza in Alberta 2015-2016 Season Analytics and Performance Reporting Branch August 2016 For more information contact: Analytics and Performance Reporting Branch Health Standards,
More informationThe Impact of Pandemic Influenza on Public Health
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationTechnology appraisal guidance Published: 25 February 2009 nice.org.uk/guidance/ta168
Amantadine, oseltamivir and zanamivir for the treatment of influenza Technology appraisal guidance Published: 25 February 2009 nice.org.uk/guidance/ta168 NICE 2018. All rights reserved. Subject to Notice
More informationInfluenza. Paul K. S. Chan Department of Microbiology The Chinese University of Hong Kong
Influenza Paul K. S. Chan Department of Microbiology The Chinese University of Hong Kong Influenza Virus Nomenclature Influenza virus A, B & C Influenza A : Haemagglutinin (H), neuraminidase (N) A H3N2,
More informationInfluenza RN.ORG, S.A., RN.ORG, LLC
Influenza WWW.RN.ORG Reviewed May, 2017, Expires May, 2019 Provider Information and Specifics available on our Website Unauthorized Distribution Prohibited 2017 RN.ORG, S.A., RN.ORG, LLC PURPOSE: This
More informationFull Season Immunization: A New Paradigm Is Evolving Update
Full Season Immunization: A New Paradigm Is Evolving 28 Update Why Is a New Paradigm Needed? It is medically relevant to vaccinate throughout the entire influenza season Influenza immunization recommendations
More informationA multidisciplinary scientifically independent network of. European Scientists Fighting Influenza 2014
European Scientists Fighting Influenza 2014 A multidisciplinary scientifically independent network of Members: Independent influenza experts Advisors: experts with additional advisory roles Partners: patient
More informationNothing to disclose. Influenza Update. Influenza Biology. Influenza Biology. Influenza A 12/15/2014
Influenza Update Nothing to disclose. Lisa Winston, MD UCSF / San Francisco General Hospital Divisions of Infectious Diseases and Hospital Medicine Influenza Biology Influenza Biology Influenza viruses
More informationCloudbreak. January Cidara Therapeutics
Cloudbreak January 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationHuman infection with pandemic (H1N1) 2009 virus: updated interim WHO guidance on global surveillance
Human infection with pandemic (H1N1) 2009 virus: updated interim WHO guidance on global surveillance 10 July 2009 Background This document updates the interim WHO guidance on global surveillance of pandemic
More informationTable 1: Summary of Texas Influenza (Flu) and Influenza-like Illness (ILI) Activity for the Current Week Texas Surveillance Component
Texas Surveillance Report 2017 2018 Season/2018 MMWR Week 03 (Jan. 14, 2018 Jan. 20, 2018) Report produced on 1/27/2018 Summary activity remains high across the state of Texas. Compared to the previous
More informationUPDATE ON INFLUENZA IN A YEAR OF VACCINE SHORTAGE
UPDATE ON INFLUENZA IN A YEAR OF VACCINE SHORTAGE Brian Goldstein, M.D., M.B.A. Andrew Kaplan, M.D. Melissa Miller, Ph.D David Jay Weber, M.D., M.P.H. THE INFLUENZA VACCINE SHORTAGE Manufacturers and estimated
More informationH1N1: Pediatric Surge Capacity Strategies and Lessons Learned
H1N1: Pediatric Surge Capacity Strategies and Lessons Learned Daniel B. Fagbuyi, MD, FAAP MAJ, MC, USAR Medical Director, Disaster Preparedness and Emergency Management Children s s National Medical Center,
More informationOpen Clinical Trial Data for All? The Paradox of Transparency. Alasdair Breckenridge
Open Clinical Trial Data for All? The Paradox of Transparency Alasdair Breckenridge Should the public have access to data on which regulatory decisions are taken? Advantages and disadvantages of increased
More informationInfluenza A(H1N1)2009 pandemic Chronology of the events in Belgium
Arch Public Health 2010, 68, 48-52 Influenza A(H1N1)2009 pandemic Chronology of the events in Belgium by Litzroth A 1, Gutiérrez I 1,2, Hammadi S 1 Keywords Belgium, chronology, epidemiology, influenza
More informationIs the Neuraminidase Inhibitor Tamiflu Effective in the Treatment of Influenza?
The Science Journal of the Lander College of Arts and Sciences Volume 9 Number 1 Fall 2015 Article 11 1-1-2015 Is the Neuraminidase Inhibitor Tamiflu Effective in the Treatment of Influenza? Eliyakim Hershkop
More informationAmantadine, oseltamivir and zanamivir for the treatment of influenza. Review of NICE technology appraisal guidance 58
Issue date: February 2009 Review date: November 2013 Amantadine, oseltamivir and zanamivir for the treatment of influenza Review of NICE technology appraisal guidance 58 NICE technology appraisal guidance
More informationPEDIATRIC INFLUENZA CLINICAL PRACTICE GUIDELINES
PEDIATRIC INFLUENZA CLINICAL PRACTICE GUIDELINES DEFINITIONS AND BACKGROUND Uncomplicated influenza illness is characterized by the abrupt onset of constitutional and respiratory signs and symptoms. Signs
More informationWhat Antivirals Can Be Used for 2009 H1N1 Influenza?
www.upmc-biosecurity.org www.upmc-cbn.org May 13, 2009 The Use of Antivirals for 2009 H1N1 Influenza Virus Infection By Ann Norwood, MD, Brooke Courtney, JD, MPH, Eric Toner, MD, and Amesh Adalja, MD Use
More information